Contact Us

In addition to assembling a diversified team with expertise in each area of branding, investor relations, public relations and social media, we have developed a network of brands and partners to best serve both public and private companies. By engaging any one of our services, you will benefit from decades of experience accumulated by helping more than 250 companies achieve greater success.

Contact Us

    Your Name *

    Your Email *

    Subject

    Message:

    Get Your Copy of The StocksToBuyNow Newsletter

    You’re just a click and email verification away from joining hundreds of other subscribers receiving weekly trading ideas!

    From Our Blog

    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

    March 31, 2026

    LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing […]

    Rotate your device 90° to view site.